Facing broad pushback from industry, White House backs down on FDA's Covid-19 vaccine guidance
Facing thinly-veiled criticism from the nation’s largest drugmaking lobby and a direct refutation from the CEO of the leading Covid-19 vaccine developer, the White House has backed off of its efforts to block FDA guidance that would place stricter requirements for a coronavirus vaccine to win authorization, several outlets reported.
The move likely means that Pfizer’s vaccine will not meet the FDA’s standards before Election Day, as President Donald Trump has repeatedly promised over the objection of his own public health officials and independent experts.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,500+ biopharma pros reading Endpoints daily — and it's free.